Pluvicto Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Lutetium (¹⁷⁷Lu) vipivotide tetraxetan

Indications/Uses

Prostate-specific membrane antigen +ve metastatic castration-resistant prostate cancer in adult patients who have been treated w/ androgen receptor pathway inhibitor & taxane-based chemotherapy.

Dosage/Direction for Use

IV Recommended dose: 7.4 GBq (200 mCi) every 6 wk (±1 wk) for a total of 6 doses.

Contraindications

Hypersensitivity.

MIMS Class

Targeted Cancer Therapy

ATC Classification

V10XX05 - lutetium (177Lu) vipivotide tetraxetan ; Belongs to the class of various therapeutic radiopharmaceuticals.

Regulatory Classification

POM

Presentation/Packing

Form

Pluvicto soln for inj 1,000 MBq/mL

Packing/Price

1's

Pluvicto

lutetium (177lu) vipivotide tetraxetan

Manufacturer:

Advanced Accelerator